Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents
07:30am - 03:35pm EDT - April 6, 2024


Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents icon

Abstract: JNCCN23-0640 https://jnccn.org/view/journal...


Author(s):
Tags: Member Institution Clinical Oncology Top Abstract

Display Label Action
Madanat_NCCN2024_IMerge_Poster_FINAL_28Feb2024.pdf Download Handout